Generic Version
-
{
- All
- News
- Videos
-
Affordable Semaglutide Is Coming: Should You Be Worried About Drug Safety, Health Risks And Side Effects?
India's healthcare landscape will change as semaglutide patents expire in 2026, allowing over 50 generic versions to enter the market and improve access for diabetes and obesity treatment.
-
Affordable Semaglutide Is Coming: Should You Be Worried About Drug Safety, Health Risks And Side Effects?
India's healthcare landscape will change as semaglutide patents expire in 2026, allowing over 50 generic versions to enter the market and improve access for diabetes and obesity treatment.
-
Zydus Cadila Launches India's Cheapest Remdesivir Version At Rs 2,800 Per Vial
It (Remdesivir version) will be sold under the brand name Remdac to government and private hospitals treating Covid-19 patients, the company said in a regulatory filing.
-
Zydus Cadila Launches India's Cheapest Remdesivir Version At Rs 2,800 Per Vial
It (Remdesivir version) will be sold under the brand name Remdac to government and private hospitals treating Covid-19 patients, the company said in a regulatory filing.
-
Viagra's Own Generic, Cheaper Version By Pfizer To Hit Markets Soon
Just before other generic versions could hit the market, Pfizer came out with his own generic version of Viagra. This will help Pfizer Inc. avoiding the large amount of sales drop after markets will be flooded with numerous generic and cheaper versions of the impotence pill.
-
Sun Pharma Bets on Cut-Price Gleevec To Boost US Sales
Sun Pharma launched a generic version of Novartis's leukaemia drug Gleevec on Monday in the United States and hopes to poach a third of sales in six months by pricing the copycat some 30 per cent cheaper, Sun's North American chief executive said.
-
Ranbaxy stops production of its generic Lipitor: US drug regulator
Ranbaxy Laboratories has stopped production of its generic version of cholesterol lowering drug Lipitor until it investigates the issue of potential glass particles in certain lots, the US health regulator has said.
-
Affordable Semaglutide Is Coming: Should You Be Worried About Drug Safety, Health Risks And Side Effects?
India's healthcare landscape will change as semaglutide patents expire in 2026, allowing over 50 generic versions to enter the market and improve access for diabetes and obesity treatment.
-
Affordable Semaglutide Is Coming: Should You Be Worried About Drug Safety, Health Risks And Side Effects?
India's healthcare landscape will change as semaglutide patents expire in 2026, allowing over 50 generic versions to enter the market and improve access for diabetes and obesity treatment.
-
Zydus Cadila Launches India's Cheapest Remdesivir Version At Rs 2,800 Per Vial
It (Remdesivir version) will be sold under the brand name Remdac to government and private hospitals treating Covid-19 patients, the company said in a regulatory filing.
-
Zydus Cadila Launches India's Cheapest Remdesivir Version At Rs 2,800 Per Vial
It (Remdesivir version) will be sold under the brand name Remdac to government and private hospitals treating Covid-19 patients, the company said in a regulatory filing.
-
Viagra's Own Generic, Cheaper Version By Pfizer To Hit Markets Soon
Just before other generic versions could hit the market, Pfizer came out with his own generic version of Viagra. This will help Pfizer Inc. avoiding the large amount of sales drop after markets will be flooded with numerous generic and cheaper versions of the impotence pill.
-
Sun Pharma Bets on Cut-Price Gleevec To Boost US Sales
Sun Pharma launched a generic version of Novartis's leukaemia drug Gleevec on Monday in the United States and hopes to poach a third of sales in six months by pricing the copycat some 30 per cent cheaper, Sun's North American chief executive said.
-
Ranbaxy stops production of its generic Lipitor: US drug regulator
Ranbaxy Laboratories has stopped production of its generic version of cholesterol lowering drug Lipitor until it investigates the issue of potential glass particles in certain lots, the US health regulator has said.
